Financial Analysis Of A Vaccination Campaign Using 13 Valent Pneumococcal Conjugated Vaccine (PCV13) With Employers

Abstract

diseases are a public health priority in Colombia. The aim of this study was to estimate the difference of cases and costs from serotype coverage of pneumococcal conjugated vaccines of 10 and 13 serotypes (PCV10 and PCV13, respectively) in population under 5 years old in Colombia. Methods: A deterministic model was built for a cohort of children born in 2011. The probabilities of incidence, mortality and sequelae of pneumonia, meningitis, sepsis, and acute otitis media and clinical effectiveness of PCV10 and PCV13 for this population, were determined through a systematic literature review. Vaccination scheme 2+1 was included, herd effect of 42% and population coverage of 84.09% was assumed for both vaccines. The differences between the evaluated vaccines were estimated in terms of opportunity costs and net profit. The study was conducted from the perspective of third-party payers and a time horizon of 5 years. Costs were expressed in 2012 USD (exchange rate US$1 = $1798.23 COP). Results: A cohort of 652,611 children was assumed. Model showed a higher protection with PCV13 in comparison to PCV10. With PCV13 a difference of 98 prevented deaths for meningitis, pneumonia and sepsis was observed.

The full benefits of adult pneumococcal vaccination: A systematic review

“…The most commonly captured benefit from the broad perspective was outcome-related productivity gains. Sixteen studies (10.7%) included this benefit [ 74 – 76 , 81 , 85 , 87 , 98 , 108 , 115 , 117 , 127 , 132 , 142 , 144 , 157 , 165 ]. These studies estimated how much work individuals miss due to a case of pneumococcal disease and compute the value of that missed work by multiplying missed time by the wage rate.…”

“…Even within the literature that examines benefits other than our narrow ones, study quality and reporting are at times limited. For example, of the 17 unique studies that account for at least one broad benefit, seven (41.2%) present only study abstracts [ 75 , 81 , 85 , 87 , 98 , 115 , 144 ]. Of the remaining 10 studies [ 74 , 76 , 108 , 117 , 127 , 132 , 142 , 157 , 160 , 165 ], other limitations abound, including, for example, borrowing epidemiological trend data from other countries [ 108 ], lack of data necessitating many assumptions and low estimate precision [ 157 ], and possible confounding due to a study’s observational nature [ 160 ].…”

“…Interestingly, three economic modeling studies—two from Brazil and one from Mexico—took an employer’s perspective to analyze the effects of vaccinating employees against pneumococcal disease on outcome-related productivity gains [ 81 , 85 , 98 ]. While the three studies presented only abstracts, and are therefore inconclusive by themselves, their findings unanimously favored the benefits of adult pneumococcal vaccination.…”

“…Twenty-seven (84.4%) of these PCV13-only studies account for healthcare cost savings [ 55 , 63 , 64 , 80 , 82 , 87 , 91 , 98 , 110 , 117 , 123 , 127 , 128 , 130 – 132 , 150 , 151 , 153 , 156 – 158 , 168 , 173 , 178 , 184 , 194 ], compared with 79 (52.7%) of all included studies. Similarly, seven of these studies (21.9%) account for outcome-related productivity gains [ 81 , 87 , 98 , 117 , 127 , 132 , 157 ], which represents double the share of all included studies (10.7%).…”